Alder is developing eptinezumab for the preventive treatment of migraine in adults. Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. In addition, by acquiring Alder, Lundbeck will further enhance its capabilities to deliver future biological innovations in brain diseases. Headquartered in Copenhagen, Denmark, Lundbeck has international production facilities in Denmark, Italy and France and affiliates or sales offices in more than 50 countries. The offer to purchase, the related letter of transmittal and the solicitation/recommendation statement will be made available for free at the SEC’s website at www.sec.gov. To participate in the conference call please follow the instructions belowIf you prefer operator assistance to register for the call, please call in 10 minutes prior using one of these phone numbers: (No PIN code required):About the eptinezumab PROMISE clinical trial program (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) was a phase III randomized, double-blind, placebo-controlled international trial evaluating the safety and efficacy of eptinezumab for prevention of episodic migraine.
We operate in more than 57 countries around the world. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. 2009;49(7):1028–1041 Hepp, Z, Dodick DW, Varon SF, et al. The solicitation and offer to buy the common stock of Alder will only be made pursuant to an offer to purchase and related tender offer materials. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure. Lundbeck A/S (Lundbeck) and Alder BioPharmaceuticals (NASDAQ: ALDR) (Alder) today announced a definitive agreement for Lundbeck to acquire Alder. At the time the Offer is commenced, Lundbeck will file a tender offer statement on Schedule TO and thereafter Alder will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the Offer. It operates through the following geographical segments: Europe, the Unites States of America, and International Markets. Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. Company profile page for Lundbeck Pharmaceuticals Ltd including stock price, company news, press releases, executives, board members, and contact information Other AEs included upper respiratory infection, nausea and urinary tract infection, arthralgia (joint pain), dizziness, anxiety and fatigue, which all occurred at a similar incidence to placebo (less than 2% difference vs. placebo) in the pooled data set.Eptinezumab is an investigational monoclonal antibody (mAb) discovered and developed by Alder BioPharmaceuticals for migraine prevention. In Alder’s interim report for the second quarter of 2019, the net loss for the first six months was USD 176.3 million. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The acquisition of Alder will support Lundbeck’s aim to deliver long-term sustainable growth and is consistent with capital allocation priorities. The majority of the spend is focused on ensuring that Alder is prepared for the potential launch of eptinezumab in the first quarter of 2020, including advancing eptinezumab’s supply chain, building commercial inventory, continuing to build out Alder’s commercial footprint and other pre-launch market readiness activities.The expected impact from the transaction on Lundbeck's profitability in 2019 will depend on the timing of the closing of the transaction. Our pipeline consists of several R&D programs and our products are available in more than 100 countries. Lundbeck intends to leverage its proven expertise in neuroscience, and its highly effective organization across 56 countries, to maximize the opportunity to serve patients suffering from brain diseases, including migraine. However, on a pro forma basis assuming the transaction is closed on 1 November 2019, Lundbeck expects to incur transaction costs of approximately 200 million related to the acquisition of Alder and integration and retention costs of DKK 400-500 million.